| Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526) |
|---|
| 04/20/2011 | EP2311952A2 Antibodies to MRT-1 protein or fragments thereof |
| 04/20/2011 | EP2311951A1 Novel MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1 |
| 04/20/2011 | EP2311950A1 Novel MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1 |
| 04/20/2011 | EP2311944A1 Polypeptides and polynucleotides from coagulase-negative staphylococci |
| 04/20/2011 | EP2311882A1 Reducing the immunogenicity of fusion proteins |
| 04/20/2011 | EP2311872A1 Albumin fusion proteins |
| 04/20/2011 | EP2311871A2 IL-1 antagonist stable liquid formulation |
| 04/20/2011 | EP2311870A1 Compositions and methods for the treatment of immune related diseases |
| 04/20/2011 | EP2311869A1 Use of mammalian cytokine; related reagents |
| 04/20/2011 | EP2311868A1 Compositions and methods for the treatment of immune related diseases |
| 04/20/2011 | EP2311867A1 Trimeric binding proteins for trimeric cytokines |
| 04/20/2011 | EP2311866A1 GAG binding proteins |
| 04/20/2011 | EP2311865A1 Placental Growth Factor in Cancer Disease |
| 04/20/2011 | EP2311864A1 Recombinant protein-s composition |
| 04/20/2011 | EP2311863A1 Nucleic acid and corresponding protein entitled 121P1F1 useful in treatment and detection of cancer |
| 04/20/2011 | EP2311862A2 Differential in tumour gene products and use of same |
| 04/20/2011 | EP2311861A2 Differential in tumour gene products and use of same |
| 04/20/2011 | EP2311860A2 Differential in tumour gene products and use of same |
| 04/20/2011 | EP2311859A1 Uses of a novel Eimeria gene and corresponding protein |
| 04/20/2011 | EP2311858A1 Improved fluorescence proteins, production and use of same |
| 04/20/2011 | EP2311857A1 polypeptides involved in regulation of sugar and lipid metabolism and methods of use VIII |
| 04/20/2011 | EP2311856A1 Polypeptides involved in regulation of sugar and lipid metabolism and methods of use VIII |
| 04/20/2011 | EP2311855A2 Bacillus licheniformis YvnA negative strain |
| 04/20/2011 | EP2311854A1 Mutated pseudomonas exotoxins with reduced antigenicity |
| 04/20/2011 | EP2311853A1 Infectious cDNA of an approved vaccine strain of measles virus. Use for immunogenic compositions |
| 04/20/2011 | EP2311852A1 Anti-infarction molecules |
| 04/20/2011 | EP2311851A2 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
| 04/20/2011 | EP2311849A1 Specific binding agents of human angiopoietin-2 |
| 04/20/2011 | EP2311848A1 Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection |
| 04/20/2011 | EP2311500A1 Labeling targeting agents with gallium-68 and gallium-67 |
| 04/20/2011 | EP2311487A2 Identification of surface-associated antigens for tumour diagnosis and therapy |
| 04/20/2011 | EP2311484A1 Use of IL-12 and IL-12 antagonists for the manufacture of a pharmaceutical composition for the treatment of autoimmune diseases |
| 04/20/2011 | EP2311482A1 Osteogenic synthetic BMP-7 peptides, pharmaceutical compositions cell culture medium containing same |
| 04/20/2011 | EP2311481A2 Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor |
| 04/20/2011 | EP2311480A1 Compstatin analogs with improved activity |
| 04/20/2011 | EP2311479A1 Compstatin analogs with improved activity |
| 04/20/2011 | EP2311478A1 Use of ip3 receptor-binding protein for controlling intracellular pH |
| 04/20/2011 | EP2311477A1 Use of ip3 receptor-binding protein for controlling phosphatidylinositol metabolism |
| 04/20/2011 | EP2311469A2 Methods and compositions for tissue regeneration |
| 04/20/2011 | EP2311468A1 Gene overexpressed in cancer |
| 04/20/2011 | EP2311436A1 Stabilized protein crystals, formulations containing them and methods of making them |
| 04/20/2011 | EP2311432A1 Prevention and reduction of blood loss |
| 04/20/2011 | EP2310861A1 Healthy kidney biomarkers |
| 04/20/2011 | EP2310523A1 Methods for enhanced production of bone morphogenetic proteins |
| 04/20/2011 | EP2310515A1 Method to obtain transgenic plants resistant to phytopathogen attack based on rna interference (rnai) |
| 04/20/2011 | EP2310509A1 Tnfsf single chain molecules |
| 04/20/2011 | EP2310508A1 Tgf-b antagonist multi-target binding proteins |
| 04/20/2011 | EP2310417A1 Oxidized ldl specific antibody-fusion and conjugated proteins |
| 04/20/2011 | EP2310411A1 Recombinant fibrinogen |
| 04/20/2011 | EP2310410A2 Tnf- antagonist multi-target binding proteins |
| 04/20/2011 | EP2310409A2 Multimeric tnf receptors |
| 04/20/2011 | EP2310408A2 Thyroid stimulating hormone fusion proteins |
| 04/20/2011 | EP2310407A2 Biologically active peptidomimetic macrocycles |
| 04/20/2011 | EP2310406A2 Insulin fusion polypeptides |
| 04/20/2011 | EP2310405A1 Peptide inhibitors of cd40l signaling and uses therefor |
| 04/20/2011 | EP2310404A1 Transconjugants of lactic acid bacteria |
| 04/20/2011 | EP2310403A2 New bacteriophage adhesion proteins |
| 04/20/2011 | EP2310402A1 Bridged secondary amines and use thereof as iap bir domain binding compounds |
| 04/20/2011 | EP2310062A1 Use of immobilized antagonists for enhancing growth factor containing bioimplant effectiveness |
| 04/20/2011 | EP2310038A2 Treatment of hearing and balance impairments using compounds having erythropoietin activity |
| 04/20/2011 | EP2310035A2 Fibroblast growth factor (fgf) analogs and uses thereof |
| 04/20/2011 | EP2309873A1 Soluble canola protein isolate production |
| 04/20/2011 | EP1941045B1 Use of a nucleic acid sequence for the generation of a transgenic plant having enhanced drought tolerance |
| 04/20/2011 | EP1874312B1 Treatment of hpv induced anogenital intraepithelial neoplasia |
| 04/20/2011 | EP1670926B1 Modified cea /b7 vector |
| 04/20/2011 | EP1640455B1 Fluorescent protein |
| 04/20/2011 | EP1639141B1 Methods for treating lentivirus infections |
| 04/20/2011 | EP1624892B1 Therapeutic use of anti-cs1 antibodies |
| 04/20/2011 | EP1572734B1 Peptides impairing pbx dependent gene regulation |
| 04/20/2011 | EP1427826B1 HIV- RT-nef-Gag codon optimised DNA vaccines |
| 04/20/2011 | EP1385993B1 Method of detecting and treating tuberous sclerosis complex associated disorders |
| 04/20/2011 | EP1104481B1 Plant expression vectors |
| 04/20/2011 | CN1964737B Methods of using IL-1 antagonists to treat autoinflammatory disease |
| 04/20/2011 | CN1849395B HLA-a24 binding cancer antigen peptide derived from ribin |
| 04/20/2011 | CN1835763B CCN1 compositions and methods |
| 04/20/2011 | CN1795265B Control of stem cell differentiation induction and differentiation potency |
| 04/20/2011 | CN1789412B Reconstruction of 5-enol pyruvoyl shikimic acid-3-phosphate synthetase activity by utilizing fragment complementation technique |
| 04/20/2011 | CN1643148B Mouse spermatogenesis genes, human male sterility-associated genes and diagnostic system using the same |
| 04/20/2011 | CN1628179B Detection of hepatocellular carcinoma |
| 04/20/2011 | CN1551918B Genetically modified ecarin and process for producing the same |
| 04/20/2011 | CN102027123A Recombinant production of authentic human proteins using human cell expression systems |
| 04/20/2011 | CN102027121A Methods and compositions for root knot nematode control |
| 04/20/2011 | CN102027120A Plants having enhanced yield-related traits and a method for making the same |
| 04/20/2011 | CN102027114A Articular cartilage gene therapy with recombinant vector encoding BMP-7 |
| 04/20/2011 | CN102027019A High-density lipoprotein-like peptide-phospholipid scaffold (''HPPS'') nanoparticles |
| 04/20/2011 | CN102027008A Growth factor-mimicking peptides and uses thereof |
| 04/20/2011 | CN102027007A Long-acting Y2 and/or Y4 receptor agonists |
| 04/20/2011 | CN102027006A Novel and powerful MHC-class II petptides derived from survivin |
| 04/20/2011 | CN102027005A Purification of peptides prepared by solid phase synthesis |
| 04/20/2011 | CN102027004A Polypeptides having alpha-amylase activity and polynucleotides encoding same |
| 04/20/2011 | CN102027003A Chlamydia antigens |
| 04/20/2011 | CN102026667A Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use |
| 04/20/2011 | CN102026658A Improved immunizing composition |
| 04/20/2011 | CN102026655A Lipocalin-2 as a prognostic and diagnostic marker for heart and stroke risks |
| 04/20/2011 | CN102026654A Oxygen-transferring blood substitute and a pharmaceutical composition (variants) |
| 04/20/2011 | CN102026653A Human factor IX variants with an extended half life |
| 04/20/2011 | CN102023220A Methods of diagnosing cervical cancer |
| 04/20/2011 | CN102021186A Magnaporthe grisea MoPPF3 gene and function and application of coding protein of magnaporthe grisea MoPPF3 gene |
| 04/20/2011 | CN102021185A Function and usage of magnaporthe oryzae MoCHS1 gene and coded protein thereof |
| 04/20/2011 | CN102021184A Antigenic polypeptides |